A class of cyclometalated RhIII complexes [Cp*Rh(ppy)(SR)]
bearing thiolate ligands, Cp* = pentamethylcyclopentadienyl, ppy =
2-phenylpyridinate, and R = pyridyl (Spy, 2), pyrimidyl
(SpyN, 3), benzimidazolyl (Sbi, 4), and
benzothiazolyl (Sbt, 5), were produced and identified
by means of spectroscopic methods. The in vitro cytotoxicity
of the RhIII compounds in three different human mortal
cancerous cell lines (ovarian, SKOV3; breast, MCF-7; lung, A549) and
a normal lung (MRC-5) cell line were evaluated, indicating the selectivity
of these cyclometalated RhIII complexes to cancer cells.
Complex 5, selected for in vivo experiment,
has shown an effective inhibition of tumor growth in SKOV3 xenograft
mouse model relative to control (p-values < 0.05
and < 0.01). Importantly, the outcomes of H&E (hematoxylin
and eosin) staining and hematological analysis revealed negligible
toxicity of 5 compared to cisplatin on a functioning
of the main organs of mouse. Molecular docking, UV–vis, and
emission spectroscopies (fluorescence, 3D fluorescence, synchronous)
techniques were carried out on 1–5 to peruse the mechanism of the anticancer activities of these complexes.
The obtained data help to manifest the binding affinity between the
rhodium compounds and calf thymus DNA (CT-DNA) through the interaction
by DNA minor groove and moderate binding affinity with bovine serum
albumin (BSA), particularly with the cavity in the subdomain IIA.
It can be concluded that the Rh-thiolate complexes are highly promising
leads for the development of novel effective DNA-targeted anticancer
drugs.